RMD - ResMed Inc.

Top 50 High-Quality Dividend Growth Stocks For October 2026

I track an investable universe of 50 high-quality dividend growth stocks to identify attractive entry points based on valuation and future return potential. Applied Materials, D.R. Horton, and Home Depot saw notable ranking improvements due to upgraded EPS growth estimates and/or favorable valuation shifts. 44 out of 50 stocks currently offer a forward return estimate of at least 10%, with 32 appearing potentially undervalued based on free cash flow mean reversion.

Oct 11, 2026 08:46 AM • seekingalpha.com

ResMed (NYSE:RMD) CEO Sells $1,129,613.03 in Stock

ResMed Inc. (NYSE: RMD - Get Free Report) CEO Michael Farrell sold 4,991 shares of the business's stock in a transaction that occurred on Wednesday, October 7th. The stock was sold at an average price of $226.33, for a total value of $1,129,613.03. Following the sale, the chief executive officer directly owned 479,803 shares in the

Oct 11, 2026 01:39 AM • defenseworld.net

Resmed to Report First Quarter Fiscal 2027 Earnings on October 29, 2026

SAN DIEGO, Oct. 01, 2026 (GLOBE NEWSWIRE) -- Resmed (NYSE: RMD, ASX: RMD) today announced it plans to release financial and operational results for the first quarter of fiscal year 2027 on Thursday, October 29, 2026, after the New York Stock Exchange closes. Following the release, Resmed management will host a webcast to discuss the results. Other forward-looking and material information may also be discussed during the webcast.

Oct 01, 2026 12:05 PM • globenewswire.com

ResMed Targets 12%-14% EPS Growth as GLP-1 Patients Lift Sleep Therapy Demand

ResMed (NYSE: RMD) outlined its growth outlook, margin strategy and portfolio plans during a Morgan Stanley discussion, with executives emphasizing demand generation, patient adherence and ongoing product innovation in sleep and respiratory care. Chairman and Chief Executive Officer Mick Farrell said the company has issued guidance for 5% to 7% core constant-currency revenue growth, including an

Sep 22, 2026 02:03 AM • defenseworld.net

ResMed Targets 12%-14% EPS Growth as GLP-1 Patients Lift Sleep Therapy Demand

ResMed NYSE: RMD outlined its growth outlook, margin strategy and portfolio plans during a Morgan Stanley discussion, with executives emphasizing demand generation, patient adherence and ongoing product innovation in sleep and respiratory care.

Sep 21, 2026 12:02 PM • marketbeat.com

Engineers Gate Manager LP Has $1.58 Million Stake in ResMed Inc. $RMD

Engineers Gate Manager LP raised its stake in ResMed Inc. (NYSE: RMD) by 77.8% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 8,127 shares of the medical equipment provider's stock after acquiring an additional 3,555 shares during the period. Engineers Gate

Sep 17, 2026 12:13 AM • defenseworld.net

Sleep Device Maker ResMed Gets an Upgrade. Analysts See a Lot to Like.

Setbacks for competitors have positioned ResMed to capture more market share.

Sep 15, 2026 12:07 PM • barrons.com

Wall Street Lunch: AI Regulation Hopes Fade After Trump Calls AI Concerns A 'Hoax'

AI regulation odds have sharply declined after Trump dismissed AI takeover concerns during a public call with Nvidia (NVDA) CEO Jensen Huang. ResMed (RMD) was upgraded to Outperform by RBC Capital Markets, with a price target raised to $262, citing strong Q4 results and expected high-single-digit EPS growth.

Sep 15, 2026 10:10 AM • seekingalpha.com

ResMed Inc. (RMD) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

ResMed Inc. (RMD) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

Sep 15, 2026 09:11 AM • seekingalpha.com

Is This the Right Time to Retain Resmed Stock in Your Portfolio?

RMD's software portfolio optimization, mask innovation and solid financial health support growth, though macro pressures and competition pose risks.

Sep 15, 2026 07:10 AM • zacks.com

Here Are Tuesday’s Top Wall Street Analyst Research Calls: Autodesk, Eli Lilly, Etsy, Lear, Netskope, Nokia, Northrop Grumman, Rapid7, Rivian Automotive, Ulta Beauty, and More

Markets are rattled ahead of Wednesday's Fed decision, and Wall Street analysts are making bold moves on names like Eli Lilly, Etsy, Northrop Grumman, and Rivian. Find out which stocks got upgraded, downgraded, or newly covered before the opening bell.

Sep 15, 2026 04:04 AM • 247wallst.com

ResMed: A Significant Upside Despite The Perceived Risk

ResMed has de-rated from 30x to under 21x earnings despite 17% EPS growth, driven by narrative rather than fundamentals. Recurring mask and consumables revenue, now 42% of the sleep and breathing segment, is underappreciated and grew 13% last year. Two major risks—sleep apnea pill and reimbursement—are less material for RMD than feared; Philips' US return poses the most credible threat.

Sep 10, 2026 03:18 AM • seekingalpha.com

The IRS Lets You Send Your RMD Straight to Charity and Skip the Tax Entirely. These 3 ETFs Replace the Income You Gave Away

A Qualified Charitable Distribution can wipe your RMD off your tax return entirely, but it also kills the income you were counting on. Three ETFs can rebuild that cash flow, and they each do it a completely different way.

Sep 08, 2026 01:15 PM • 247wallst.com

ResMed Inc. $RMD Shares Purchased by Hsbc Holdings PLC

Hsbc Holdings PLC grew its position in shares of ResMed Inc. (NYSE: RMD) by 13.4% during the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 355,518 shares of the medical equipment provider's stock after buying an additional 42,007 shares during

Sep 07, 2026 11:56 PM • defenseworld.net

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ResMed Inc. - RMD

NEW YORK, Sept. 3, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of ResMed Inc. ("ResMed" or the "Company") (NYSE: RMD).

Sep 03, 2026 06:00 AM • prnewswire.com (Hide legal announcements)

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ResMed Inc. - RMD

NEW YORK, Sept. 01, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of ResMed Inc. (“ResMed” or the “Company”) (NYSE: RMD). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.

Sep 01, 2026 02:25 PM • globenewswire.com (Hide legal announcements)

Canada Pension Plan Investment Board Buys New Position in ResMed Inc. $RMD

Canada Pension Plan Investment Board bought a new stake in shares of ResMed Inc. (NYSE: RMD) in the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor bought 55,511 shares of the medical equipment provider's stock, valued at approximately $10,818,000.

Aug 30, 2026 12:26 AM • defenseworld.net

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ResMed Inc. - RMD

NEW YORK, Aug. 27, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of ResMed Inc. ("ResMed" or the "Company") (NYSE: RMD).  Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.

Aug 27, 2026 12:15 PM • prnewswire.com (Hide legal announcements)

Resmed Announces Participation in the 24th Annual Morgan Stanley Global Healthcare Conference

SAN DIEGO, Aug. 27, 2026 (GLOBE NEWSWIRE) -- Resmed (NYSE: RMD, ASX: RMD) today announced Mick Farrell, chairman and chief executive officer, and Aaron Bloomer, chief financial officer, will attend the 24th Annual Morgan Stanley Global Healthcare Conference in New York, NY on Tuesday, September 15, 2026. Resmed's webcast presentation will begin at approximately 10:00 a.m. (Eastern Time).

Aug 27, 2026 12:05 PM • globenewswire.com

228,458 Shares in ResMed Inc. $RMD Purchased by American Capital Management Inc.

American Capital Management Inc. bought a new stake in shares of ResMed Inc. (NYSE: RMD) in the undefined quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund bought 228,458 shares of the medical equipment provider's stock, valued at approximately $44,522,000. ResMed accounts

Aug 27, 2026 01:15 AM • defenseworld.net

RBC Capital Upgrades ResMed (RMD) to Outperform

$262.00 (was $222.99)

Craig Wong-Pan · RBC Capital

Sep 15, 2026 03:58 AM • StreetInsider

ResMed price target raised to $267 from $255 at KeyBanc

$267.00 (was $240.33)

KeyBanc

Aug 31, 2026 06:34 AM • TheFly

ResMed initiated with a Neutral at Rothschild & Co Redburn

$230.00 (was $219.98)

Redburn Partners

Aug 19, 2026 04:39 AM • TheFly

ResMed price target lowered to $213 from $217 at Baird

$213.00 (was $212.38)

Robert W. Baird

Aug 07, 2026 07:59 AM • TheFly

ResMed price target lowered to $255 from $260 at KeyBanc

$255.00 (was $223.24)

KeyBanc

Aug 07, 2026 06:27 AM • TheFly

ResMed (RMD) PT Lowered to $300 at UBS

$300.00 (was $195.97)

David Low · UBS

Jul 21, 2026 08:57 AM • StreetInsider

ResMed downgraded to Sector Perform from Outperform at RBC Capital

$234.00 (was $198.57)

RBC Capital

Jul 16, 2026 06:26 AM • TheFly

ResMed price target lowered to $220 from $235 at Mizuho

$220.00 (was $193.01)

Mizuho Securities

Jul 15, 2026 07:26 AM • TheFly

ResMed price target lowered to $225 from $240 at Jefferies

$225.00 (was $204.50)

Jefferies

Jul 10, 2026 09:06 AM • TheFly

ResMed price target lowered to $276 from $321 at RBC Capital

$276.00 (was $219.75)

RBC Capital

Jul 08, 2026 07:43 AM • TheFly

ResMed price target lowered to $225 from $227 at Wells Fargo

$225.00 (was $219.75)

Wells Fargo

Jul 08, 2026 06:21 AM • TheFly

ResMed price target lowered to $266 from $290 at KeyBanc

$266.00 (was $188.63)

KeyBanc

Jun 22, 2026 05:44 AM • TheFly

Morgan Stanley Downgrades ResMed (RMD) to Equalweight

$230.00 (was $193.94)

David Bailey · Morgan Stanley

Jun 17, 2026 04:13 AM • StreetInsider

ResMed price target lowered to $225 from $254 at Baird

$225.00 (was $203.87)

Robert W. Baird

May 01, 2026 08:52 AM • TheFly

ResMed price target lowered to $290 from $302 at KeyBanc

$290.00 (was $219.85)

KeyBanc

Apr 27, 2026 06:21 AM • TheFly

ResMed price target lowered to $255 from $300 at Evercore ISI

$255.00 (was $228.33)

Anthony Petrone · Evercore ISI

Apr 13, 2026 10:44 AM • TheFly

ResMed price target raised to $314 from $311 at RBC Capital

$314.00 (was $254.08)

Craig Wong-Pan · RBC Capital

Jan 30, 2026 07:54 AM • TheFly

ResMed price target raised to $265 from $260 at Stifel

$265.00 (was $257.61)

Stifel Nicolaus

Jan 30, 2026 07:40 AM • TheFly

ResMed price target raised to $302 from $299 at KeyBanc

$302.00 (was $257.61)

Brett Fishbin · KeyBanc

Jan 30, 2026 07:40 AM • TheFly

ResMed price target raised to $281 from $275 at Baird

$281.00 (was $257.61)

Robert W. Baird

Jan 30, 2026 07:25 AM • TheFly